Revolution Medicines Inc. (RVMD)
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RVMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $43.05B
- EPS (TTM)
- -$8.53
- Dividend yield
- None
- 52-week range
- 46.16 – 224.31
- Day range
- 196.25 – 203.50
- Volume / Avg
- 1.18M / 1.89M
- Beta
- —
- Shares outstanding
- 214.34M
- Next earnings
- Nov 4, 2026
52-week range
RVMD stock today
Shares of Revolution Medicines (RVMD) finished higher on Oct 7 at $200.87, a gain of 0.50% or $1.00 per share, versus the S&P 500's 0.22% decline. Shares are 10.4% below their 52-week high of $224.31, set on Aug 27, 2026 and 335.2% above the 52-week low of $46.16, near the top of the past year's range. RVMD is up 152.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 331.3%.
Revolution Medicines has posted a net loss over the last twelve months (EPS of -$8.53), so its P/E ratio is not meaningful. Revolution Medicines's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Revolution Medicines
Company profileRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Mark A. Goldsmith M.D., Ph.D.
- Headquarters
- Redwood City, CA
- Employees
- 883
- IPO year
- 2020
- Website
- revmed.com
Financial highlights
Full financialsIn fiscal 2025, Revolution Medicines generated $0 in revenue, up 0.0% from fiscal 2024. Revolution Medicines reported a net loss of $1.13 billion, compared with a loss of $600.1 million a year earlier. Diluted earnings per share came in at -$5.95.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.58M | $35.38M | $29.39M |
| Growth | — | -100.00% | -67.27% | +20.38% | -31.62% |
| Net income | $-1.13B | $-600.09M | $-436.37M | $-248.71M | $-187.09M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
Analyst forecast
ForecastConsensus (24 analysts)
strong_buy
Avg. price target
$258.84+28.86%
- Strong buy 5
- Buy 18
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-2.30
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-3.06 vs —
RVMD news
All RVMD news- Revolution Medicines: Priced For A Label The Trial Didn't Test; HoldSeeking Alpha
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?NasdaqRPRX, RVMD
- Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?NasdaqAXSM, RVMD
- 10 large and mega-cap U.S. healthcare stocks with the strongest momentum gradesSeeking Alpha
- Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?Nasdaq
- Revolution Medicines' Daraxonrasib Secures FDA Breakthrough Designation In Pancreatic CancerNasdaq
- Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?NasdaqAMGN, RVMD
- Morgan Stanley Initiates Coverage of Revolution Medicines with OverweightNasdaqRVMD, MS
Revolution Medicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIIBBiogen Inc. | 222.15 | -0.33% | $32.82B | vs RVMD |
| ARGXargenx SE ADR | 928.44 | -0.22% | $57.74B | vs RVMD |
| BNTXBioNTech SE ADR | 95.25 | -0.50% | $23.93B | vs RVMD |
| NBIXNeurocrine Biosciences Inc. | 143.47 | -1.40% | $14.58B | vs RVMD |
| EXELExelixis Inc. | 58.44 | +0.19% | $14.48B | vs RVMD |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs RVMD |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs RVMD |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs RVMD |
Indexes, lists and sector
Revolution Medicines stock FAQ
What is Revolution Medicines's stock price today?
RVMD last traded at $200.87 as of Oct 7, 4:00 PM EDT, up 0.50% on the day. Prices are delayed at least 15 minutes.
When is Revolution Medicines's next earnings date?
Revolution Medicines is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-2.30.
Who is Revolution Medicines's CEO?
Dr. Mark A. Goldsmith M.D., Ph.D. is the chief executive officer of Revolution Medicines Inc., which has about 883 employees.
What is the RVMD 52-week high?
The 52-week high for RVMD is $224.31 and the 52-week low is $46.16. The stock is currently 10.4% below its high.